 In the Forest autism trials conducted in children ages 6-12, dosing with an extended release formulation of memantine was weight-based. These weight based dose limits were selected to ensure exposure in terms of area under the curve AUC was less than the predefined limit of 2100 nghmL that represented a 10-fold lower exposure than observed at the NOAEL No observed adverse effect level of 15 mgkgday in juvenile rats. 